Business Description
Macrogenics Inc
NAICS : 325412
SIC : 2834
ISIN : US5560991094
Description
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.88 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | -0.38 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -5.22 | |||||
| Beneish M-Score | -3.74 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -20.9 | |||||
| 3-Year EPS without NRI Growth Rate | -1.6 | |||||
| 3-Year FCF Growth Rate | 16.9 | |||||
| 3-Year Book Growth Rate | -22.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.31 | |||||
| 9-Day RSI | 41.65 | |||||
| 14-Day RSI | 42.6 | |||||
| 6-1 Month Momentum % | -25.86 | |||||
| 12-1 Month Momentum % | -67.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.75 | |||||
| Quick Ratio | 3.69 | |||||
| Cash Ratio | 3.38 | |||||
| Days Inventory | 82.65 | |||||
| Days Sales Outstanding | 30.21 | |||||
| Days Payable | 338.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.3 | |||||
| Shareholder Yield % | 0.21 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95.01 | |||||
| Operating Margin % | -76.62 | |||||
| Net Margin % | -69.84 | |||||
| FCF Margin % | -44.15 | |||||
| ROE % | -77.4 | |||||
| ROA % | -36.09 | |||||
| ROIC % | -149.13 | |||||
| ROC (Joel Greenblatt) % | -217.69 | |||||
| ROCE % | -45 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.44 | |||||
| PB Ratio | 1.69 | |||||
| Price-to-Tangible-Book | 1.69 | |||||
| EV-to-EBIT | -0.35 | |||||
| EV-to-EBITDA | -0.37 | |||||
| EV-to-Revenue | 0.24 | |||||
| EV-to-Forward-Revenue | 0.91 | |||||
| EV-to-FCF | -0.54 | |||||
| Price-to-Median-PS-Value | 0.18 | |||||
| Price-to-Net-Current-Asset-Value | 2.62 | |||||
| Price-to-Net-Cash | 3.65 | |||||
| Earnings Yield (Greenblatt) % | -285.71 | |||||
| FCF Yield % | -30.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MGNX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Macrogenics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 139.773 | ||
| EPS (TTM) ($) | -1.58 | ||
| Beta | 1.51 | ||
| Volatility % | 100.27 | ||
| 14-Day RSI | 42.6 | ||
| 14-Day ATR ($) | 0.221466 | ||
| 20-Day SMA ($) | 3.3815 | ||
| 12-1 Month Momentum % | -67.17 | ||
| 52-Week Range ($) | 2.9511 - 21.88 | ||
| Shares Outstanding (Mil) | 62.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Macrogenics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Macrogenics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Macrogenics Inc Frequently Asked Questions
What is Macrogenics Inc(MGNX)'s stock price today?
The current price of MGNX is $3.26. The 52 week high of MGNX is $21.88 and 52 week low is $2.95.
When is next earnings date of Macrogenics Inc(MGNX)?
The next earnings date of Macrogenics Inc(MGNX) is 2025-03-07 Est..
Does Macrogenics Inc(MGNX) pay dividends? If so, how much?
Macrogenics Inc(MGNX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers